Análisis post hoc del estudio ARISTOTELE | 15 AGO 16

Polifarmacia en pacientes con fibrilación auricular que reciben apixaban versus warfarina

La polifarmacia se ha relacionado con un mayor riesgo de muerte y complicaciones hemorrágicas también en pacientes con fibrilación auricular.
2
4
Autor/a: Jeroen Jaspers Focks, Marc A Brouwer, Daniel M Wojdyla, Laine Thomas, Renato D Lopes, Jeffrey B Washam, Fernando Lanas, Denis Xavier, Steen Husted, clinical Lars Wallentin, John H Alexander Fuente: BMJ 2016;353:i2868  Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial
INDICE:  1. Página 1 | 2. Referencias
Referencias

GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet2015;385:117-71. doi:10.1016/S0140-6736(14)61682-2 pmid:25530442.

Nieuwlaat R, Olsson SB, Lip GYH, et al. Euro Heart Survey Investigators Euro Heart Survey on Atrial Fibrillation. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. Am Heart J2007;153:1006-12. doi:10.1016/j.ahj.2007.03.008 pmid:17540203.

Scowcroft AC, Lee S, Mant J. Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000-2009. Heart2013;99:127-32. doi:10.1136/heartjnl-2012-302843 pmid:23086966.

Singh S, Bajorek B. Pharmacotherapy in the ageing patient: the impact of age per se (a review). Ageing Res Rev2015;24:99-110. doi:10.1016/j.arr.2015.07.006 pmid:26226330.

Jyrkkä J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Patterns of drug use and factors associated with polypharmacy and excessive polypharmacy in elderly persons: results of the Kuopio 75+ study: a cross-sectional analysis. Drugs Aging2009;26:493-503. doi:10.2165/00002512-200926060-00006 pmid:19591524.

Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol2012;65:989-95. doi:10.1016/j.jclinepi.2012.02.018 pmid:22742913.

Herr M, Robine JM, Pinot J, Arvieu JJ, Ankri J. Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. Pharmacoepidemiol Drug Saf2015;24:637-46. doi:10.1002/pds.3772 pmid:25858336.

Wang R, Chen L, Fan L, et al. Incidence and effects of polypharmacy on clinical outcomes among patients aged 80+: a five-year follow-up study. PLoS One2015;10:e0142123. doi:10.1371/journal.pone.0142123 pmid:26554710.

Proietti M, Raparelli V, Olshansky B, Lip GYH. Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. Clin Res Cardiol2016;105:412-20. doi:10.1007/s00392-015-0936-y pmid:26525391.

Piccini JP, Hellkamp AS, Washam JB, et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation2016;133:352-60. doi:10.1161/CIRCULATIONAHA.115.018544 pmid:26673560.

Abdelhafiz AH, Wheeldon NM. Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice. Am J Geriatr Pharmacother2008;6:1-11. doi:10.1016/j.amjopharm.2008.03.005 pmid:18396243.

Kagansky N, Knobler H, Rimon E, Ozer Z, Levy S. Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med2004;164:2044-50. doi:10.1001/archinte.164.18.2044 pmid:15477441.

Donzé J, Clair C, Hug B, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med2012;125:773-8. doi:10.1016/j.amjmed.2012.01.033 pmid:22840664.

Leiss W, Méan M, Limacher A, et al. Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. J Gen Intern Med2015;30:17-24. doi:10.1007/s11606-014-2993-8 pmid:25143224.

Goldhaber SZ, Eriksson H, Kakkar A, et al. Influence of polypharmacy on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Circulation2015;132:A12422.
    ↵ Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med1996;156:409-16. doi:10.1001/archinte.1996.00440040081009 pmid:8607726.
    CrossRefMedlineWeb of Science
    ↵Wehinger C, Stöllberger C, Länger T, Schneider B, Finsterer J. Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation. Stroke2001;32:2246-52. doi:10.1161/hs1001.097090 pmid:11588308.

Connolly SJ, Eikelboom J, Joyner C, et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med2011;364:806-17. doi:10.1056/NEJMoa1007432 pmid:21309657.

Granger CB, Alexander JH, McMurray JJV, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med2011;365:981-92. doi:10.1056/NEJMoa1107039 pmid:21870978.

Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J2014;35:1864-72. doi:10.1093/eurheartj/ehu046 pmid:24561548.

Nobili A, Marengoni A, Tettamanti M, et al. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med2011;22:597-602. doi:10.1016/j.ejim.2011.08.029 pmid:22075287.

Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol2007;63:187-95. doi:10.1111/j.1365-2125.2006.02744.x pmid:16939529.

Lopes RD, Alexander JH, Al-Khatib SM, et al. ARISTOTLE Investigators. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J2010;159:331-9. doi:10.1016/j.ahj.2009.07.035 pmid:20211292.

World Health Organization Collaborating Centre for Drug Statistics Methodology (WHOCC). 2015. www.whocc.no/atc_ddd_index.

US Food and Drug Administration (FDA). 2014. www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm.

Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest2008;133(suppl):160S-98S. doi:10.1378/chest.08-0670 pmid:18574265.

Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost1993;69:236-9.pmid:8470047.

Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost2005;3:692-4. doi:10.1111/j.1538-7836.2005.01204.x pmid:15842354.

Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med1999;131:492-501. doi:10.7326/0003-4819-131-7-199910050-00003 pmid:10507957.

Lip GYH, Laroche C, Dan GA, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace2014;16:308-19. doi:10.1093/europace/eut373 pmid:24351881.

Halperin JL, Hankey GJ, Wojdyla DM, et al. ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with non-valvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation2014;130:138-46. doi:10.1161/CIRCULATIONAHA.113.005008 pmid:24895454.

Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol2014;63:2141-7. doi:10.1016/j.jacc.2014.02.549 pmid:24657685.

Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost2010;104:1099-105. doi:10.1160/TH10-07-0491 pmid:20886196.

White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med2007;167:239-45. doi:10.1001/archinte.167.3.239 pmid:17296878.

Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart2005;91:472-7. doi:10.1136/hrt.2004.042465 pmid:15772203.

Prins MH, Lensing AWA, Bauersachs R, et al. EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J2013;11:21. doi:10.1186/1477-9560-11-21 pmid:24053656.

Singh M, Stewart R, White H. Importance of frailty in patients with cardiovascular disease. Eur Heart J2014;35:1726-31. doi:10.1093/eurheartj/ehu197 pmid:24864078.

Fried LP, Tangen CM, Walston J, et al. Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci2001;56:M146-56. doi:10.1093/gerona/56.3.M146 pmid:11253156.

Benetos A, Rossignol P, Cherubini A, et al. Polypharmacy in the aging patient: management of hypertension in octogenarians. JAMA2015;314:170-80. doi:10.1001/jama.2015.7517 pmid:26172896.

 

Comentarios

Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí